This announcement is a separate document:
华仁药业:关于全资子公司己酮可可碱原料药获得上市申请批准通知书的公告
Huaren Pharmaceutical: Announcement regarding the approval notice for the listing application of the wholly-owned subsidiary's active pharmaceutical ingredient Ketoprofen.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.